Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 PR Newswire - Mon Mar 30, 7:30AM CDT

GERMANTOWN, Md. , March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.12 (+0.98%)
Precigen Reports Full Year 2025 Financial Results and Business Updates PR Newswire - Wed Mar 25, 3:05PM CDT

GERMANTOWN, Md. , March 25, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.12 (+0.98%)
Precigen Faces Mounting Losses as Analysts Brace for Widening Deficit Barchart - Tue Mar 24, 4:06PM CDT

PGEN : 4.12 (+0.98%)
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 PR Newswire - Wed Mar 11, 3:05PM CDT

GERMANTOWN, Md. , March 11, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.12 (+0.98%)
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Mon Jan 12, 7:00AM CST

GERMANTOWN, Md. , Jan. 12, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.12 (+0.98%)
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Mon Jan 5, 3:05PM CST

GERMANTOWN, Md. , Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President...

PGEN : 4.12 (+0.98%)
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 PR Newswire - Thu Nov 6, 2025

GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the...

PGEN : 4.12 (+0.98%)
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis PR Newswire - Mon Oct 13, 2025

GERMANTOWN, Md. , Oct. 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives...

PGEN : 4.12 (+0.98%)
Precigen Announces Up to $125 Million Non-Dilutive Financing PR Newswire - Wed Sep 3, 2025

$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and...

PGEN : 4.12 (+0.98%)
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug Zacks Investment Research - Mon Aug 25, 2025

Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...

KNSA : 57.54 (+4.11%)
PGEN : 4.12 (+0.98%)
CRMD : 7.89 (+1.28%)
INO : 1.1400 (+3.64%)

Barchart Exclusives

Ahead of Palantir Earnings, Here Is What Barchart Options Data Shows for PLTR Stock Barchart - 4 minutes ago
Options traders believe Palantir stock will push higher on Q1 earnings today, after market close. But HSBC downgraded PLTR shares to “neutral” heading into the quarterly release. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.